This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Epizyme, Inc. To Present At Upcoming Conferences In September

CAMBRIDGE, Mass., Aug. 28, 2013 /PRNewswire/ --  Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in upcoming September conferences.

  • Citi 8th Annual Biotech Day at the Mandarin Oriental Hotel in Boston, Mass. on Wednesday, September 4 th
  • JMP Securities Biotech Day at the Langham Hotel in Boston, Mass. on Friday, September 6 th at 11:00 a.m. ET.
  • Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York, N.Y. on Wednesday, September 11 th at 8:00 a.m. ET. A live webcast will be available at this link or by visiting the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.
  • Stifel Nicolaus Healthcare Conference 2013 at the Four Seasons Hotel in Boston, Mass. on Thursday, September 12 th at 2:05 p.m. ET. A live webcast will be available at this link or by visiting the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.
  • BioPharm America Conference at the Westin Boston Waterfront in Boston, Mass. on Tuesday, September 17 th at 2:45 p.m. ET in a panel discussion titled "Partnering: Thinking beyond the deal."
  • Cancer Advance Boston at the Harvard Medical School in Boston, Mass. on Thursday, September 19 th at 3:00 p.m. ET in a panel discussion titled "Redefining Cancer: Insights from Cancer Stem Cells, Epigenetics, Immunotherapy and More."
  • LES Annual Meeting at the Philadelphia Marriott Downtown in Philadelphia, Pa. on Monday, September 23 rd at 12:15 p.m. ET to receive the 2013 LES Deal of Distinction Award in the Life Sciences Sector.
  • Discovery On Target 2013 at the Westin Boston Waterfront in Boston, Mass. on Tuesday, September 24 th at 11:45 a.m. ET, presenting on targeting histone methyltransferases in cancer therapy.
  • BioCentury's NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center in New York, N.Y. on Friday, September 27 th at 9:00 a.m. ET. A live webcast will be available at this link or by visiting the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.

About Epizyme, Inc.Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit  http://www.epizyme.com and connect with us on Twitter at  @EpizymeRx.

SOURCE Epizyme, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs